RT Journal Article
SR Electronic
T1 Deep skin dysbiosis in vitiligo patients: link with mitochondrial and immune changes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20163469
DO 10.1101/2020.07.29.20163469
A1 Bzioueche, Hanene
A1 Sjodin, Kotryna Simonyte
A1 West, Christina E
A1 Khemis, Abdallah
A1 Rocchi, Stephane
A1 Passeron, Thierry
A1 Tulic, Meri K
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.29.20163469.abstract
AB Rationale: Vitiligo is an autoimmune-disease characterized by patchy, white skin due to melanocyte loss. Commensal cutaneous or gut dysbiosis have been linked to various dermatological disorders. Here, we studied skin and gut microbiota of vitiligo patients compared to healthy controls. Methods: We recruited 20 subjects and obtained swabs and biopsies from lesional and non-lesional skin, stool and blood from each individual (total 100 samples). Results: We detected reduced richness and distribution of microbiota in stool of vitiligo subjects compared to controls (P<0.01). Skin swabs had greater alpha-diversity than skin biopsies (P<0.001), however only trends were seen between groups when examining microbiota at the skin surface. This was in contrast to sampling deeper layers of skin from the same patients which showed decreased richness and distribution of species (P<0.01) but greater phylogenetic diversity (P<0.01) in lesional compared to non-lesional sites. Biopsy microbiota from the lesional skin had distinct microbiota composition which was depleted of protective Bifidobacterium and enriched in Terenicutes, Streptococcus, Mycoplasma and mitochondrial DNA (P<0.001); the latter was linked with increased innate immunity and stress markers in the blood of the same patients (P<0.05). Conclusion: These data describe vitiligo-specific cutaneous and gut microbiota and, for the first time in humans, a link between mitochondrial alteration, innate immunity and skin microbiota.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from ISISPharma. The funding source had no involvement in study design, collection, analysis or interpretation of the data or in writing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Ethics Committee (N14.028) and was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data have been deposited to the Sequence Read Archive (SRA) under accession number PRJNA639425. All other data that support the findings of this study are available from the corresponding authors upon reasonable request.